The recombinant proteins market size is expected to advance at a CAGR of 11.2% during 2022–2030, to reach USD 3,203.7 million by 2030.
This is ascribed to the rising demand for novel therapeutic proteins and biologics, growing usage of recombinant proteins in research and clinical applications, evolving healthcare needs, and surging adoption of innovative technologies in the medical field.
Additionally, the growing consumer awareness regarding the benefits of biopharmaceuticals developed using recombinant proteins and the rising investment in research and development in emerging economies will drive the growth of the global recombinant proteins industry over the coming years.
Technological advancements are supporting the market expansion owing to the developments in a variety of methods used for the synthesis of recombinant proteins. The production of alternative cell lines and enhanced cell culture techniques, as well as new expression technologies, such as mammalian cell expression, baculovirus expression, and E. coli expression, has facilitated and streamlined the production of recombinant proteins.
For instance, in January 2022, Alamar Biosciences announced a partnership with Abcam plc for exploring the human proteome, to power innovations in research, diagnostics, and therapeutics. Together, they will produce an automated proteomics platform using the nucleic acid-linked immune-sandwich assay (NULISA) technology.
Moreover, the advancements in bioreactor systems have considerably increased the yield of the products in less time. As per the National Center for Biotechnology Information (NCBI), approximately 65.6% of the clinical-scale producers and about 42% of the commercial manufacturers leverage single-use bioreactors to expand bioprocessing outputs.
The recombinant metabolic enzymes category is expected to witness the fastest growth during the forecast period. The key factor driving the growth of this product category is the rising usage of these enzymes in various research studies on wound repair, transplantation, oncology, and COVID-19.
The Asia-Pacific market is expected to witness the highest CAGR, of about 14%, during the forecast period, on account of the rising prevalence of chronic disorders in emerging economies, such as India and China. In addition to that, the rise in the public and private funding for recombinant protein research and development is fueling the market.
The robust government support for small and medium-sized recombinant technology enterprises, along with an expansive healthcare network, is also projected to drive the region's market. Moreover, the developing countries including South Korea, China, and India; the rising population, and surging diabetes incidence are expected to drive the growth of the market in the forecast period. For instance, according to the Lancet Diabetes & Endocrinology journal, approximately 8.4 million people had type 1 diabetes worldwide in 2021, with India home to the third-largest population of such people.
Furthermore, the favorable healthcare regulations of governments and the development of advanced techniques in proteomic and genomic research are contributing to the growth of the market.
The most-significant recombinant proteins market players are Thermo Fisher Scientific Inc., Merck KGaA, Abcam plc, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Miltenyi Biotec, ACROBiosystems, RayBiotech Life Inc., Aviva Systems Biology Corporation, and Enzo Life Sciences Inc.